Vaccine Contract Manufacturing Market by Vaccine Type (DNA, Inactivated, Live Attenuated), Technology Platform (Cell Based, Cell Free, Egg Based), Service Offering, Application Type, Application Stage, End User - Global Forecast 2025-2032
Description
The Vaccine Contract Manufacturing Market was valued at USD 5.51 billion in 2024 and is projected to grow to USD 6.04 billion in 2025, with a CAGR of 9.53%, reaching USD 11.43 billion by 2032.
A strategic framing of vaccine contract manufacturing that situates capacity resilience, platform specialization, and regulatory readiness at the center of industry decision-making
The landscape of vaccine contract manufacturing has entered a phase of sustained strategic importance for public health, industry players, and national security planners. In a world where rapid response capacity and complex biologics production must coexist, contract manufacturing partners function as both industrial enablers and strategic risk mitigators. This introduction situates the reader in a context where advanced platform technologies, regulatory complexity, and geopolitical factors intersect to reshape capacity planning and partner selection.
Leaders in biotech, government procurement, and pharmaceutical development must reconcile competing pressures: the need for flexible surge capacity, the economics of specialized production, and the imperative to maintain stringent quality and regulatory compliance. Consequently, evaluation criteria have evolved beyond unit cost and lead time to include platform expertise, integrated analytical capability, and demonstrated ability to support late-stage commercial supply. The following sections synthesize the most consequential shifts and actionable perspectives that business leaders should factor into their strategic roadmaps for manufacturing partnerships and capability investments.
Transformative technology advances and regulatory evolution driving a new era of integrated, flexible and high-compliance vaccine contract manufacturing
Vaccine contract manufacturing is being transformed by a confluence of technological, regulatory, and market-driven shifts that redefine how capacity is procured and deployed. Technology platforms such as cell-based and synthetic approaches are enabling faster development cycles and increased molecular diversity, while modular facility designs and single-use systems are reducing turnaround times and enabling swifter repurposing of capacity across programs. These engineering and platform innovations are complemented by more rigorous analytical services and fill-finish capabilities that allow outsourced partners to assume greater technical responsibility in biologics programs.
At the same time, regulatory expectations have evolved to emphasize process understanding, data integrity, and supply chain transparency. This trend compels contract manufacturers to invest in advanced analytics and digital traceability to support regulatory submissions and real-time quality oversight. Strategic partnerships are now evaluated for their ability to provide end-to-end solutions that encompass drug substance, formulation, fill-finish, and supporting analytical services. The result is a higher bar for integration and technical depth among third-party manufacturers, and a market that rewards providers able to deliver demonstrable technical competencies, flexible capacity options, and proven regulatory execution across complex vaccine modalities.
How new 2025 tariff dynamics are reshaping sourcing, nearshoring, and logistics strategies for resilient vaccine manufacturing and supply continuity
The introduction of new tariff measures in the United States for 2025 is reshaping vendor selection criteria and supply chain architectures for vaccine production. Tariff adjustments increase the relative cost of imported components and finished goods, incentivizing firms to reassess sourcing strategies and to prioritize domestically located suppliers when total landed cost, lead time, and regulatory alignment are considered together. This shift elevates the strategic importance of domestic contract manufacturing capacity, as buyers weigh the tradeoffs between cost, reliability, and geopolitical risk.
In response, many organizations are accelerating nearshoring and reshoring initiatives to reduce exposure to tariff fluctuations and transit-related disruption. These decisions often require re-evaluating existing supplier contracts, capital allocation for local capacity, and collaborative models that share development risk with domestic partners. Importantly, tariff-driven changes also influence inventory policies and logistics planning, prompting a rebalancing between just-in-time delivery and strategic safety stocks. The interplay between tariffs and regulatory considerations means that manufacturers and sponsors are increasingly factoring customs, classification, and compliance implications into early-stage sourcing decisions to sustain program timelines and protect product integrity.
A granular segmentation-driven perspective illuminating how vaccine type, platform, service, application stage, and end-user profiles redefine partner selection and capability requirements
Insightful segmentation reveals where capabilities, risk, and opportunity concentrate across vaccine contract manufacturing. Based on Vaccine Type, distinctions among DNA, Inactivated, Live Attenuated, mRNA, Toxoid, and Viral Vector products drive differences in process complexity, cold chain requirements, and analytical burden, influencing partner selection and facility fit. Based on Technology Platform, choices among Cell Based, Cell Free, Egg Based, and Synthetic Peptide production determine capital intensity, process scalability, and contamination risk; within Cell Based approaches, the divergence between Adherent Cell Culture and Suspension Cell Culture further refines capacity planning and facility design requirements.
Based on Service Offering, the range from Analytical Services, Drug Substance Manufacturing, Fill Finish, Formulation Services, Logistics, to Packaging outlines potential integration points where a provider can capture value and reduce handoffs for sponsors. Based on Application Type, the operational demands differ significantly between Preventive Vaccines and Therapeutic Vaccines, with therapeutic programs typically requiring more complex clinical and regulatory support. Based on Application Stage, distinctions between Clinical Stage and Commercial Stage programs-and within Clinical Stage across Phase I, Phase II, and Phase III-dictate the flexibility and scale a contract manufacturer must offer to support program progression. Based on End User, the needs of Biotech Companies, Government Agencies, and Pharmaceutical Companies vary by risk tolerance, contracting cadence, and expectations for intellectual property stewardship, all of which should inform partnership models and contractual frameworks.
Regional dynamics and jurisdictional nuances that shape strategic site selection, regulatory pathways, and partnership priorities across global vaccine manufacturing hubs
Regional considerations influence where investments in capacity and partnerships will yield the greatest strategic advantage. In the Americas, strong biomanufacturing ecosystems coexist with evolving policy emphasis on domestic capacity and supply chain security, shaping an environment favorable to integrated end-to-end providers and strategic public-private collaborations. Europe, Middle East & Africa present a complex patchwork of regulatory regimes and manufacturing competencies, where centralized EU regulatory harmonization coexists with region-specific access and procurement mechanisms, calling for partners with multi-jurisdictional regulatory experience and flexible distribution networks. Asia-Pacific hosts a broad spectrum of capabilities from highly specialized CMO sites to rapidly expanding industrial capacity, underpinned by a dynamic supplier base and targeted government incentives that accelerate local capability development.
These regional dynamics affect decisions about where to locate critical operations, how to hedge supply risk, and which provider attributes-regulatory track record, logistics reach, or platform specialization-are most important. Sponsors and buyers should match program-specific requirements against regional strengths; for example, early-stage clinical supply might leverage Asia-Pacific agility or Americas regulatory proximity, while complex fill-finish or rapid scale-up could require providers with proven multi-region execution and regulatory filing experience across European and North American authorities. Ultimately, regional strategy must balance operational efficiency with geopolitical and regulatory resilience.
Key company-level differentiators including platform depth, integrated analytics, and digital supply chain capabilities that drive competitive advantage in contract manufacturing
Leading contract manufacturers and service providers are differentiating through investments in platform-specific expertise, analytical depth, and modular capacity that supports rapid program transitions. Companies that combine advanced cell culture proficiency, single-use automation, and robust aseptic fill-finish capabilities position themselves to capture diversified engagements that span clinical proof-of-concept through commercial continuity. Additionally, firms that integrate comprehensive analytical services and in-house stability and release testing reduce program risk and accelerate regulatory filings by minimizing inter-organizational handoffs.
Strategic differentiation also arises from supply chain visibility and digitalization; providers with integrated ERP systems, electronic batch records, and serialized packaging capabilities demonstrate higher operational transparency and compliance readiness. Partnerships between CMOs and specialized technology vendors-covering areas such as high-throughput analytics, mRNA lipid nanoparticle formulation, or cell banking-are increasingly common as a way to expand technical scope without linear capital investment. For buyers, the vendor landscape requires a nuanced evaluation of technical pedigree, track record across relevant vaccine modalities, and the ability to co-invest in process optimization or capacity expansion when programs advance toward broader clinical or commercial milestones.
Practical and finance-aware strategic actions for sponsors and providers to strengthen resilience, accelerate timelines, and align incentives in manufacturing partnerships
Industry leaders should pursue a set of actionable moves to strengthen resilience, accelerate program timelines, and capture strategic value. First, prioritize partner assessments that weight platform competence and integrated analytical capability equally with capacity availability, ensuring that technical fit reduces downstream risk and regulatory friction. Second, develop flexible contracting frameworks and joint investment models that enable rapid capacity ramp-up while sharing financial risk with manufacturing partners. Such arrangements can include capacity reservation clauses, milestone-based fee structures, and co-development agreements that align incentives across development phases.
Third, invest in supply chain visibility and classification reviews to mitigate tariff exposure and optimize landed cost structures; early customs and regulatory alignment will reduce downstream surprises. Fourth, encourage modular facility design and single-use technologies to facilitate faster repurposing and lower cross-contamination risk, thereby improving responsiveness to emergent needs. Fifth, cultivate multi-region supplier portfolios that combine domestic capabilities for critical components with international partners for specialized services, balancing geopolitical risk and operational agility. Taken together, these actions will help sponsors and providers navigate complexity while preserving program timelines and product quality.
An evidence-based methodology that integrates executive interviews, regulatory and technical validation, and supplier capability triangulation to inform practical decision-making
This research synthesizes primary interviews with senior manufacturing, regulatory, and supply chain leaders, supplemented by rigorous secondary analysis of regulatory guidance, technical publications, and public filings to ensure a comprehensive view of current capabilities and evolving practices. Primary inputs included structured interviews with manufacturing executives, quality and regulatory heads, and procurement specialists who manage contract arrangements and capacity planning. These perspectives were triangulated with facility disclosures, regulatory inspection outcomes, and technology adoption case studies to validate claims of technical capability and integration depth.
Methodological rigor was maintained through cross-validation of provider capabilities against documented regulatory outcomes and third-party certifications. The analysis emphasizes qualitative assessment of platform readiness, analytical scope, and logistical footprint rather than quantitative sizing, enabling actionable insights for decision-makers seeking to compare providers and design resilient procurement strategies. Limitations include variability in public disclosure and the proprietary nature of some contractual terms; where necessary, anonymized interview findings were aggregated to preserve confidentiality while reflecting common industry practices and emergent trends.
A concise conclusion emphasizing integration, resilience, and the necessity of aligning platform capabilities with regional and regulatory realities for long-term success
Vaccine contract manufacturing now operates at the nexus of technological innovation, regulatory expectation, and strategic supply chain management. The cumulative effect of advanced platform adoption, tariff-driven sourcing shifts, and heightened regulatory scrutiny means that sponsors must adopt a more sophisticated, integrated approach to partner selection and supply planning. Success will favor organizations that prioritize technical fit, operational transparency, and contractual flexibility while maintaining a multi-region perspective to hedge geopolitical and logistical risks.
Going forward, the ability to mobilize integrated service offerings-combining drug substance, formulation, fill-finish, and analytical release testing-will be a key determinant of program speed and reliability. In parallel, investments in digital traceability and supply chain analytics will continue to enhance regulatory readiness and operational resilience. For stakeholders across biotech, government, and pharma, the imperative is clear: align manufacturing strategy with platform realities and regional constraints to ensure continuity, quality, and the capacity to respond rapidly to emerging public health needs.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic framing of vaccine contract manufacturing that situates capacity resilience, platform specialization, and regulatory readiness at the center of industry decision-making
The landscape of vaccine contract manufacturing has entered a phase of sustained strategic importance for public health, industry players, and national security planners. In a world where rapid response capacity and complex biologics production must coexist, contract manufacturing partners function as both industrial enablers and strategic risk mitigators. This introduction situates the reader in a context where advanced platform technologies, regulatory complexity, and geopolitical factors intersect to reshape capacity planning and partner selection.
Leaders in biotech, government procurement, and pharmaceutical development must reconcile competing pressures: the need for flexible surge capacity, the economics of specialized production, and the imperative to maintain stringent quality and regulatory compliance. Consequently, evaluation criteria have evolved beyond unit cost and lead time to include platform expertise, integrated analytical capability, and demonstrated ability to support late-stage commercial supply. The following sections synthesize the most consequential shifts and actionable perspectives that business leaders should factor into their strategic roadmaps for manufacturing partnerships and capability investments.
Transformative technology advances and regulatory evolution driving a new era of integrated, flexible and high-compliance vaccine contract manufacturing
Vaccine contract manufacturing is being transformed by a confluence of technological, regulatory, and market-driven shifts that redefine how capacity is procured and deployed. Technology platforms such as cell-based and synthetic approaches are enabling faster development cycles and increased molecular diversity, while modular facility designs and single-use systems are reducing turnaround times and enabling swifter repurposing of capacity across programs. These engineering and platform innovations are complemented by more rigorous analytical services and fill-finish capabilities that allow outsourced partners to assume greater technical responsibility in biologics programs.
At the same time, regulatory expectations have evolved to emphasize process understanding, data integrity, and supply chain transparency. This trend compels contract manufacturers to invest in advanced analytics and digital traceability to support regulatory submissions and real-time quality oversight. Strategic partnerships are now evaluated for their ability to provide end-to-end solutions that encompass drug substance, formulation, fill-finish, and supporting analytical services. The result is a higher bar for integration and technical depth among third-party manufacturers, and a market that rewards providers able to deliver demonstrable technical competencies, flexible capacity options, and proven regulatory execution across complex vaccine modalities.
How new 2025 tariff dynamics are reshaping sourcing, nearshoring, and logistics strategies for resilient vaccine manufacturing and supply continuity
The introduction of new tariff measures in the United States for 2025 is reshaping vendor selection criteria and supply chain architectures for vaccine production. Tariff adjustments increase the relative cost of imported components and finished goods, incentivizing firms to reassess sourcing strategies and to prioritize domestically located suppliers when total landed cost, lead time, and regulatory alignment are considered together. This shift elevates the strategic importance of domestic contract manufacturing capacity, as buyers weigh the tradeoffs between cost, reliability, and geopolitical risk.
In response, many organizations are accelerating nearshoring and reshoring initiatives to reduce exposure to tariff fluctuations and transit-related disruption. These decisions often require re-evaluating existing supplier contracts, capital allocation for local capacity, and collaborative models that share development risk with domestic partners. Importantly, tariff-driven changes also influence inventory policies and logistics planning, prompting a rebalancing between just-in-time delivery and strategic safety stocks. The interplay between tariffs and regulatory considerations means that manufacturers and sponsors are increasingly factoring customs, classification, and compliance implications into early-stage sourcing decisions to sustain program timelines and protect product integrity.
A granular segmentation-driven perspective illuminating how vaccine type, platform, service, application stage, and end-user profiles redefine partner selection and capability requirements
Insightful segmentation reveals where capabilities, risk, and opportunity concentrate across vaccine contract manufacturing. Based on Vaccine Type, distinctions among DNA, Inactivated, Live Attenuated, mRNA, Toxoid, and Viral Vector products drive differences in process complexity, cold chain requirements, and analytical burden, influencing partner selection and facility fit. Based on Technology Platform, choices among Cell Based, Cell Free, Egg Based, and Synthetic Peptide production determine capital intensity, process scalability, and contamination risk; within Cell Based approaches, the divergence between Adherent Cell Culture and Suspension Cell Culture further refines capacity planning and facility design requirements.
Based on Service Offering, the range from Analytical Services, Drug Substance Manufacturing, Fill Finish, Formulation Services, Logistics, to Packaging outlines potential integration points where a provider can capture value and reduce handoffs for sponsors. Based on Application Type, the operational demands differ significantly between Preventive Vaccines and Therapeutic Vaccines, with therapeutic programs typically requiring more complex clinical and regulatory support. Based on Application Stage, distinctions between Clinical Stage and Commercial Stage programs-and within Clinical Stage across Phase I, Phase II, and Phase III-dictate the flexibility and scale a contract manufacturer must offer to support program progression. Based on End User, the needs of Biotech Companies, Government Agencies, and Pharmaceutical Companies vary by risk tolerance, contracting cadence, and expectations for intellectual property stewardship, all of which should inform partnership models and contractual frameworks.
Regional dynamics and jurisdictional nuances that shape strategic site selection, regulatory pathways, and partnership priorities across global vaccine manufacturing hubs
Regional considerations influence where investments in capacity and partnerships will yield the greatest strategic advantage. In the Americas, strong biomanufacturing ecosystems coexist with evolving policy emphasis on domestic capacity and supply chain security, shaping an environment favorable to integrated end-to-end providers and strategic public-private collaborations. Europe, Middle East & Africa present a complex patchwork of regulatory regimes and manufacturing competencies, where centralized EU regulatory harmonization coexists with region-specific access and procurement mechanisms, calling for partners with multi-jurisdictional regulatory experience and flexible distribution networks. Asia-Pacific hosts a broad spectrum of capabilities from highly specialized CMO sites to rapidly expanding industrial capacity, underpinned by a dynamic supplier base and targeted government incentives that accelerate local capability development.
These regional dynamics affect decisions about where to locate critical operations, how to hedge supply risk, and which provider attributes-regulatory track record, logistics reach, or platform specialization-are most important. Sponsors and buyers should match program-specific requirements against regional strengths; for example, early-stage clinical supply might leverage Asia-Pacific agility or Americas regulatory proximity, while complex fill-finish or rapid scale-up could require providers with proven multi-region execution and regulatory filing experience across European and North American authorities. Ultimately, regional strategy must balance operational efficiency with geopolitical and regulatory resilience.
Key company-level differentiators including platform depth, integrated analytics, and digital supply chain capabilities that drive competitive advantage in contract manufacturing
Leading contract manufacturers and service providers are differentiating through investments in platform-specific expertise, analytical depth, and modular capacity that supports rapid program transitions. Companies that combine advanced cell culture proficiency, single-use automation, and robust aseptic fill-finish capabilities position themselves to capture diversified engagements that span clinical proof-of-concept through commercial continuity. Additionally, firms that integrate comprehensive analytical services and in-house stability and release testing reduce program risk and accelerate regulatory filings by minimizing inter-organizational handoffs.
Strategic differentiation also arises from supply chain visibility and digitalization; providers with integrated ERP systems, electronic batch records, and serialized packaging capabilities demonstrate higher operational transparency and compliance readiness. Partnerships between CMOs and specialized technology vendors-covering areas such as high-throughput analytics, mRNA lipid nanoparticle formulation, or cell banking-are increasingly common as a way to expand technical scope without linear capital investment. For buyers, the vendor landscape requires a nuanced evaluation of technical pedigree, track record across relevant vaccine modalities, and the ability to co-invest in process optimization or capacity expansion when programs advance toward broader clinical or commercial milestones.
Practical and finance-aware strategic actions for sponsors and providers to strengthen resilience, accelerate timelines, and align incentives in manufacturing partnerships
Industry leaders should pursue a set of actionable moves to strengthen resilience, accelerate program timelines, and capture strategic value. First, prioritize partner assessments that weight platform competence and integrated analytical capability equally with capacity availability, ensuring that technical fit reduces downstream risk and regulatory friction. Second, develop flexible contracting frameworks and joint investment models that enable rapid capacity ramp-up while sharing financial risk with manufacturing partners. Such arrangements can include capacity reservation clauses, milestone-based fee structures, and co-development agreements that align incentives across development phases.
Third, invest in supply chain visibility and classification reviews to mitigate tariff exposure and optimize landed cost structures; early customs and regulatory alignment will reduce downstream surprises. Fourth, encourage modular facility design and single-use technologies to facilitate faster repurposing and lower cross-contamination risk, thereby improving responsiveness to emergent needs. Fifth, cultivate multi-region supplier portfolios that combine domestic capabilities for critical components with international partners for specialized services, balancing geopolitical risk and operational agility. Taken together, these actions will help sponsors and providers navigate complexity while preserving program timelines and product quality.
An evidence-based methodology that integrates executive interviews, regulatory and technical validation, and supplier capability triangulation to inform practical decision-making
This research synthesizes primary interviews with senior manufacturing, regulatory, and supply chain leaders, supplemented by rigorous secondary analysis of regulatory guidance, technical publications, and public filings to ensure a comprehensive view of current capabilities and evolving practices. Primary inputs included structured interviews with manufacturing executives, quality and regulatory heads, and procurement specialists who manage contract arrangements and capacity planning. These perspectives were triangulated with facility disclosures, regulatory inspection outcomes, and technology adoption case studies to validate claims of technical capability and integration depth.
Methodological rigor was maintained through cross-validation of provider capabilities against documented regulatory outcomes and third-party certifications. The analysis emphasizes qualitative assessment of platform readiness, analytical scope, and logistical footprint rather than quantitative sizing, enabling actionable insights for decision-makers seeking to compare providers and design resilient procurement strategies. Limitations include variability in public disclosure and the proprietary nature of some contractual terms; where necessary, anonymized interview findings were aggregated to preserve confidentiality while reflecting common industry practices and emergent trends.
A concise conclusion emphasizing integration, resilience, and the necessity of aligning platform capabilities with regional and regulatory realities for long-term success
Vaccine contract manufacturing now operates at the nexus of technological innovation, regulatory expectation, and strategic supply chain management. The cumulative effect of advanced platform adoption, tariff-driven sourcing shifts, and heightened regulatory scrutiny means that sponsors must adopt a more sophisticated, integrated approach to partner selection and supply planning. Success will favor organizations that prioritize technical fit, operational transparency, and contractual flexibility while maintaining a multi-region perspective to hedge geopolitical and logistical risks.
Going forward, the ability to mobilize integrated service offerings-combining drug substance, formulation, fill-finish, and analytical release testing-will be a key determinant of program speed and reliability. In parallel, investments in digital traceability and supply chain analytics will continue to enhance regulatory readiness and operational resilience. For stakeholders across biotech, government, and pharma, the imperative is clear: align manufacturing strategy with platform realities and regional constraints to ensure continuity, quality, and the capacity to respond rapidly to emerging public health needs.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing demand for mRNA vaccine contract manufacturing capacity accelerated by pandemic preparedness strategies
- 5.2. Increasing partnerships between biotech firms and CMOs to scale up personalized cancer vaccine production pipelines
- 5.3. Adoption of single-use bioreactor technologies to enhance flexibility and reduce cross-contamination risks in vaccine manufacturing
- 5.4. Regulatory harmonization efforts streamlining quality and compliance requirements across major vaccine production jurisdictions
- 5.5. Investment surge in fill-finish capabilities to address global shortages of vials and syringes and expedite vaccine distribution
- 5.6. Integration of digital twins and real-time analytics for process optimization and predictive maintenance in vaccine CMO facilities
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Vaccine Contract Manufacturing Market, by Vaccine Type
- 8.1. DNA
- 8.2. Inactivated
- 8.3. Live Attenuated
- 8.4. MRNA
- 8.5. Toxoid
- 8.6. Viral Vector
- 9. Vaccine Contract Manufacturing Market, by Technology Platform
- 9.1. Cell Based
- 9.1.1. Adherent Cell Culture
- 9.1.2. Suspension Cell Culture
- 9.2. Cell Free
- 9.3. Egg Based
- 9.4. Synthetic Peptide
- 10. Vaccine Contract Manufacturing Market, by Service Offering
- 10.1. Analytical Services
- 10.2. Drug Substance Manufacturing
- 10.3. Fill Finish
- 10.4. Formulation Services
- 10.5. Logistics
- 10.6. Packaging
- 11. Vaccine Contract Manufacturing Market, by Application Type
- 11.1. Preventive Vaccines
- 11.2. Therapeutic Vaccines
- 12. Vaccine Contract Manufacturing Market, by Application Stage
- 12.1. Clinical Stage
- 12.1.1. Phase I
- 12.1.2. Phase Ii
- 12.1.3. Phase Iii
- 12.2. Commercial Stage
- 13. Vaccine Contract Manufacturing Market, by End User
- 13.1. Biotech Companies
- 13.2. Government Agencies
- 13.3. Pharmaceutical Companies
- 14. Vaccine Contract Manufacturing Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Vaccine Contract Manufacturing Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Vaccine Contract Manufacturing Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. AbbVie Inc
- 17.3.2. Ajinomoto Co., Inc.
- 17.3.3. Aton (Shanghai) Biotech Co., Ltd.
- 17.3.4. Avid Bioservices, Inc.
- 17.3.5. Catalent, Inc.
- 17.3.6. Charles River Laboratories International, Inc.
- 17.3.7. CSL Limited
- 17.3.8. Curia Global, Inc.
- 17.3.9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- 17.3.10. Emergent BioSolutions Inc.
- 17.3.11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
- 17.3.12. Gedeon Richter PLC
- 17.3.13. GlaxoSmithKline PLC
- 17.3.14. ICON PLC
- 17.3.15. IDT Biologika GmbH
- 17.3.16. KBI Biopharma, Inc. by JSR Corporation
- 17.3.17. Klocke Pharma-Service GmbH
- 17.3.18. Lonza Group Ltd.
- 17.3.19. Merck KGaA
- 17.3.20. Moderna, Inc.
- 17.3.21. Pfizer Inc.
- 17.3.22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
- 17.3.23. Recipharm AB
- 17.3.24. Serum Institute of India
- 17.3.25. Vetter Pharma-Fertigung GmbH & Co. KG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
